We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 23 MARCH 2022
Humira's End Of Reign
Rothwell, Figg, Ernst & Manbeck, P.C.
On March 8, 2022, Alvotech announced that it has executed a U.S. settlement agreement with Abbvie that grants Alvotech non-exclusive rights to market AVT02 (adalimumab) in the U.S starting July 1, 2023.
United StatesIntellectual Property








